Swanbridge Capital
  • Home
  • Our Story
  • Strategy
  • Portfolio
  • Team
  • News & Events
  • Contact
Select Page

Swanbridge invests in Pan Cancer T

by stefan | Feb 8, 2021 | Blog

Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and Van Herk Ventures with support from...

Recent Posts

  • IMMAGENE announces seed investment round to progress novel Immuno-Oncology therapeutics
  • Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
  • Swanbridge invests in Pan Cancer T
  • Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
  • Swanbridge Capital invests in Immagene

Recent Comments

    Archives

    • November 2021
    • October 2021
    • February 2021
    • November 2020
    • September 2020
    • October 2019
    • April 2019
    • December 2018
    • July 2018
    • December 2017
    • October 2017
    • December 2016

    Categories

    • Blog
    • Geen categorie

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by Elegant Themes | Powered by WordPress